Multicriteria Decision Analysis Applied to the Clinical Use of Pharmacotherapy for Overactive Bladder Symptom Complex
Chapple C. R., Mironska E., Wagg A., Milsom I., Diaz D. C., Koelbl H., Pushkar D., Tubaro A., De R. D., Chartier-Kastler E., Phillips L. D.
European Urology Focus
Vol.6, Issue3, P. 522-530
Опубликовано: 2020
Тип ресурса: Обзор
DOI:10.1016/j.euf.2019.09.020
Аннотация:
Context: The nonspecific storage symptom complex overactive bladder (OAB) is an important clinical condition in functional urology. Until recently, pharmacological therapy comprised antimuscarinic drugs, but more recently beta 3 agonists have added to the available agents. Traditional reporting of efficacy and safety of these agents relies upon regulatory placebo-controlled studies. There remains no head-to-head comparison of existing agents in the contemporary literature. Contemporary conclusions on comparative efficacy and safety drawn from the use of these agents are based on systematic reviews of the literature and associated meta-analyses. Objective: In this study, we used the analytical model of multicriteria decision analysis (MCDA) to compare contemporary pharmacotherapy for OAB. Evidence acquisition: Efficacy and safety data from published, randomised, placebo-controlled trials of antimuscarinic antagonists, the beta 3 agonist, and the combination of an antimuscarinic and beta
Ключевые слова:
Antimuscarinic; Beta 3; Multicriteria decision analysis; Overactive bladder; Pharmacotherapy
darifenacin; fesoterodine; mirabegron; oxybutynin; solifenacin; tolterodine; trospium chloride; aging; constipation; dizziness; drug efficacy; drug safety; drug tolerability; evidence based medicine; headache; human; multicriteria decision analysis; nocturia; outcome assessment; overactive bladder; personalized medicine; quality of life; Review; risk benefit analysis; sensitivity analysis; symptom; tachycardia; urinary tract infection; urinary urgency; urine incontinence; urine retention; xerostomia
Язык текста: Английский
ISSN: 2405-4569
Chapple C. R.
Mironska E.
Wagg A.
Milsom I.
Diaz D. C.
Koelbl H.
Pushkar D.
Tubaro A.
De R. D. Ridder D.
Chartier-Kastler E.
Phillips L. D.
Чаппле C. Р.
Миронска Е.
Wагг А.
Милсом И.
Диаз Д. C.
Коелбл Х.
Пушкар Д.
Тюбаро А.
Де Р. Д. Риддер Д.
Чартиер-Кастлер Е.
Пхиллипс Л. Д.
Multicriteria Decision Analysis Applied to the Clinical Use of Pharmacotherapy for Overactive Bladder Symptom Complex
Текст визуальный непосредственный
European Urology Focus
Elsevier
Vol.6, Issue3 P. 522-530
2020
Обзор
Antimuscarinic Beta 3 Multicriteria decision analysis Overactive bladder Pharmacotherapy
darifenacin fesoterodine mirabegron oxybutynin solifenacin tolterodine trospium chloride aging constipation dizziness drug efficacy drug safety drug tolerability evidence based medicine headache human multicriteria decision analysis nocturia outcome assessment overactive bladder personalized medicine quality of life Review risk benefit analysis sensitivity analysis symptom tachycardia urinary tract infection urinary urgency urine incontinence urine retention xerostomia
Context: The nonspecific storage symptom complex overactive bladder (OAB) is an important clinical condition in functional urology. Until recently, pharmacological therapy comprised antimuscarinic drugs, but more recently beta 3 agonists have added to the available agents. Traditional reporting of efficacy and safety of these agents relies upon regulatory placebo-controlled studies. There remains no head-to-head comparison of existing agents in the contemporary literature. Contemporary conclusions on comparative efficacy and safety drawn from the use of these agents are based on systematic reviews of the literature and associated meta-analyses. Objective: In this study, we used the analytical model of multicriteria decision analysis (MCDA) to compare contemporary pharmacotherapy for OAB. Evidence acquisition: Efficacy and safety data from published, randomised, placebo-controlled trials of antimuscarinic antagonists, the beta 3 agonist, and the combination of an antimuscarinic and beta